Medicare GLP-1 Bridge Program: $50 Wegovy and Zepbound Starting July 2026

The Medicare GLP-1 Bridge is a nationwide payment demonstration run by the Centers for Medicare and Medicaid Services (CMS). It was established under Section 402(a)(1)(A) of the Social Security Amendments of 1967, a legal authority that allows CMS to test changes in payment methods to improve the efficiency and economy of Medicare services.

The Bridge was created in response to a significant gap in Medicare coverage. Since Medicare's inception, the program has been legally prohibited from covering drugs used solely for weight loss. As GLP-1 medications became widely recognized as effective treatments for obesity, millions of Medicare beneficiaries were left paying out of pocket for medications that can cost $900 or more per month without insurance.

The Bridge is not a permanent fix. It is a short-term demonstration designed to provide access while CMS collects utilization data ahead of a potential longer-term coverage expansion. The program was originally planned to run through December 31, 2026, but CMS extended it through December 31, 2027, after the longer-term BALANCE Model was delayed. You can review the official program details on the CMS Medicare GLP-1 Bridge page.

The program operates through a single central processor managed by CMS. Your Part D plan is not involved in the prior authorization, claims adjudication, or payment process. When you fill a covered prescription, you pay $50 at the pharmacy, and the pharmacy submits the claim directly to the CMS central processor for reimbursement.

Three GLP-1 medications are included in the Bridge program. All three are FDA-approved specifically for chronic weight management in adults with obesity or overweight.

Why Ozempic and Mounjaro are not covered: Ozempic (semaglutide) and Mounjaro (tirzepatide) use the same active ingredients as Wegovy and Zepbound, but they are FDA-approved for different indications, primarily type 2 diabetes. Because they have Part D-covered indications, they are excluded from the Bridge. If you take Ozempic or Mounjaro for diabetes, you continue to access those medications through your standard Part D plan.

The prescription must be for weight management: Even if you are prescribed Wegovy or Zepbound, the Bridge only applies when the prescription is specifically for weight reduction and weight management in combination with lifestyle modifications. Your prescribing doctor must attest to this when submitting the prior authorization.

If you are currently taking a GLP-1 for a Part D-covered indication and are curious how your overall drug coverage works, our guide to understanding Medicare Part D explains the benefit structure in detail.

Eligibility for the Medicare GLP-1 Bridge is based on clinical criteria that your healthcare provider must attest to when submitting a prior authorization. The baseline requirements are that you must be at least 18 years old, enrolled in a Medicare Part D plan, and prescribed the medication specifically for weight reduction and weight management in combination with ongoing lifestyle modifications.

Beyond those baseline requirements, you must fall into one of three BMI-based tiers.

Tier 1 (BMI 35 or higher): If your Body Mass Index is 35 or above at the time you begin GLP-1 therapy, you qualify with no additional diagnostic requirements. This is the most straightforward path into the program.

Tier 2 (BMI 30 to 34.9 with qualifying conditions): If your BMI is at least 30 but below 35, you can still qualify if you have been diagnosed with heart failure with preserved ejection fraction, uncontrolled hypertension despite concurrent treatment with two antihypertensive medications, or chronic kidney disease at stage 3a or above.

Tier 3 (BMI 27 to 29.9 with qualifying conditions): The lowest BMI threshold requires a diagnosis of at least one of the following: pre-diabetes as defined by American Diabetes Association guidelines, a previous myocardial infarction, a previous stroke, or symptomatic peripheral artery disease.

According to research published by the Kaiser Family Foundation, an estimated 3.8 million Medicare Part D enrollees met all of the Bridge eligibility criteria as of 2023, representing about 8 percent of all Part D enrollees. CMS has indicated it expects the program to start with single-digit millions of participants.

The Bridge was designed specifically for beneficiaries who need GLP-1 medications for weight management and who do not have an existing pathway to coverage through standard Part D. If you have a diagnosis that already qualifies you for GLP-1 coverage under Part D, you are not eligible for the Bridge, even if you also meet the BMI criteria.

The key exclusions are beneficiaries who have been diagnosed with:

Additionally, if you have already filled a GLP-1 prescription through your Part D plan in 2026, you are not eligible for the Bridge in 2026. This rule is designed to prevent existing Part D GLP-1 use from shifting to the Bridge program.

The Bridge is not a way to get a cheaper copay on a GLP-1 you are already receiving through Part D. It is exclusively for beneficiaries whose primary reason for taking the medication is weight reduction, and who do not have a Part D-covered diagnosis that provides an alternative coverage pathway.

The flat $50 monthly copay is one of the most appealing features of the Bridge program, but there are several important nuances to understand before you enroll.

What the $50 copay covers: One monthly supply of a covered GLP-1 medication (Wegovy, Zepbound, or Foundayo) at any participating pharmacy. The copay is the same regardless of the drug's list price or which benefit phase your Part D plan is in.

What the $50 copay does not include:

The LIS gap is important to understand: If you receive Extra Help (the Low-Income Subsidy program), your standard Part D drug copays are reduced to a few dollars or eliminated entirely. However, because the Bridge operates outside of Part D, those protections do not carry over. LIS beneficiaries still pay the full $50 monthly copay under the Bridge. The Kaiser Family Foundation has noted that the $50 copay may be unaffordable for some low- and modest-income beneficiaries who would otherwise qualify.

The $50 copay is consistent throughout the year: Unlike Part D cost-sharing, which changes as you move through the deductible phase, initial coverage phase, and catastrophic phase, the Bridge copay stays at $50 every month for the duration of the program. This predictability is one of the program's practical advantages.

For context on how the standard Part D benefit phases work and how they affect your drug costs, see our guide to understanding Medicare Part D coverage and costs.

Enrolling in the Medicare GLP-1 Bridge is not something you do yourself. The process begins with your healthcare provider, and it runs through a CMS central processor rather than your Part D plan.

Step 1: Talk to your doctor. Schedule an appointment to discuss whether GLP-1 therapy is appropriate for your situation. Your provider will evaluate your BMI, review your medical history for qualifying conditions, confirm you do not have a disqualifying diagnosis (type 2 diabetes, OSA, or MASH), and determine which of the three eligibility tiers applies to you.

Step 2: Your doctor submits a prior authorization. If your doctor determines you are a good candidate, they submit a prior authorization request to the CMS central processor. The request includes an attestation that you meet the clinical criteria, that the medication is being prescribed for weight management in combination with lifestyle modifications, and that you do not have a diagnosis that would qualify you for GLP-1 coverage under Part D. The prior authorization form is available directly from CMS.

Step 3: Fill your prescription at a participating pharmacy. Once the prior authorization is approved, you can fill your prescription at any participating pharmacy. You pay the $50 copay at the counter, and the pharmacy submits the claim directly to the CMS central processor. Your Part D plan is not involved in this transaction.

Step 4: Continue your prescription monthly. The Bridge covers a monthly supply. You will continue to fill your prescription monthly and pay $50 each time for the duration of the program (through December 31, 2027).

If you have questions about whether you qualify or how the Bridge interacts with your current Medicare coverage, our licensed agents can review your situation at no cost. Schedule a free Medicare consultation to get personalized guidance.

Understanding how the Bridge differs from your standard Part D drug benefit is essential for managing your overall Medicare costs.

One practical implication: if you are also taking other expensive medications through your Part D plan, the $50 you spend on Bridge GLP-1s each month will not help you reach your Part D out-of-pocket cap any faster. Your Part D spending and your Bridge spending are tracked completely separately.

To understand why the Bridge was created as a temporary demonstration rather than a permanent benefit, it helps to know the broader legislative and regulatory context.

Medicare has been legally prohibited from covering weight loss drugs since the program was established. The Balanced Budget Act of 1997 explicitly excluded drugs used for weight loss from Part D coverage. This prohibition remained in place even as GLP-1 medications transformed the treatment of obesity.

CMS's original plan for a longer-term solution was the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth). BALANCE was designed as a multi-year model that would have provided GLP-1 coverage for obesity in both Medicare and Medicaid, with a planned launch in 2027. When BALANCE was delayed, CMS extended the Bridge through December 31, 2027, to maintain access for beneficiaries while the longer-term pathway is developed.

Congress has also been working on legislation to permanently expand Medicare coverage for obesity drugs. The Treat and Reduce Obesity Act and similar proposals have been introduced in multiple sessions. As of mid-2026, no permanent legislative expansion has been enacted, but the Bridge represents the most significant step toward obesity drug coverage in Medicare's history.

For beneficiaries approaching Medicare eligibility, understanding how these coverage rules interact with your enrollment decisions is important. Our guide to Medicare Special Enrollment Periods can help you understand how life changes affect your coverage options, and our overview of Original Medicare vs. Medicare Advantage explains how drug coverage fits into each approach.

The Medicare GLP-1 Bridge does not replace or change existing Part D coverage for GLP-1 medications. It creates a new, parallel pathway specifically for weight management that operates outside of Part D.

Here is how the different GLP-1 coverage pathways currently work under Medicare:

For a deeper look at how Medicare covers Ozempic specifically, including what it costs under Part D and how to navigate prior authorization, see our dedicated guide on Medicare coverage for Ozempic.